1
Neustadt Bernard R, Gold Elijah H, Smith Elizabeth M: Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them.. Schering, May 5, 1982: EP0050800-A1 (146 worldwide citation)

Disclosed are novel carboxyalkyl dipeptides which are useful as inhibitors of angiotensinconverting enzyme and as antihypertensive agents, having the formula and the pharmaceuticallv acceptable salts thereof, wherein R and R are for example hydroxy, lower alkoxy or aryllower-4 alkoxy; R is for examp ...


2
Smith Elizabeth M, Witkowski Joseph T, Doll Ronald J, Gold Elijah H, Neustadt Bernard R, Yehaskel Albert S: Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them.. Schering, September 14, 1983: EP0088350-A1 (60 worldwide citation)

The compounds of the present invention are compounds of the formula and the pharmaceutically acceptable esters and salts thereof wherein R and R independently are hydrogen or lower alkyl; the group is one of the structures II to VIII specified @ the description, one of R, R and R is a group @ wherei ...


3
Haslanger Martin F, Sybertz Edmund Jr, Neustadt Bernard R, Smith Elizabeth M, Czarniecki Michael F, Lehman de Gaeta Laura S: Neutral metalloendopeptidase inhibitors in the treatment of hypertension.. Schering, January 27, 1988: EP0254032-A2 (14 worldwide citation)

The method of treating hypertension with neutral metalloendopeptidase (NMEP) inhibitors, NMEP inhibitors in combination with atrial peptides, and NMEP inhibitors in combination with angiotensin converting enzyme inhibitors, as well as pharmaceutical compositions therefor, are disclosed.


4
Boyle Craig D, Chackalamannil Samuel, Lankin Claire M, Shah Unmesh G, Neustadt Bernard R, Liu Hong, Stamford Andrew W: Pyrimidinone derivatives and methods of use thereof. Schering Corporation, Boyle Craig D, Chackalamannil Samuel, Lankin Claire M, Shah Unmesh G, Neustadt Bernard R, Liu Hong, Stamford Andrew W, BERGMAN Jeffrey P, October 30, 2008: WO/2008/130584 (13 worldwide citation)

The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disease, a cardiovascular disease or a disorder related to the activity of GPR119 ...


5
Xia Yan, Boyle Craig D, Greenlee William J, Chackalamannil Samuel, Jayne Charles Lee, Stamford Andrew W, Dai Xing, Harris Joel M, Neustadt Bernard R, Neelamkavil Santhosh Francis, Shah Unmesh G, Lankin Claire M, Liu Hong: Bicyclic heterocycle derivatives and methods of use thereof. Schering Corporation, Xia Yan, Boyle Craig D, Greenlee William J, Chackalamannil Samuel, Jayne Charles Lee, Stamford Andrew W, Dai Xing, Harris Joel M, Neustadt Bernard R, Neelamkavil Santhosh Francis, Shah Unmesh G, Lankin Claire M, Liu Hong, BERGMAN Jeffrey P, April 30, 2009: WO/2009/055331 (12 worldwide citation)

The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related t ...


6
Neustadt Bernard R, Hao Jinsong, Liu Hong, Boyle Craig D, Chackalamannil Samuel, Shah Unmesh G, Stamford Andrew, Harris Joel M: Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists. Schering Corporation, Neustadt Bernard R, Hao Jinsong, Liu Hong, Boyle Craig D, Chackalamannil Samuel, Shah Unmesh G, Stamford Andrew, Harris Joel M, MAGATTI Anita W, November 3, 2005: WO/2005/103055 (11 worldwide citation)

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted ar ...


7
Neelamkavil Santhosh Francis, Boyle Craig D, Neustadt Bernard R, Chackalamannil Samuel, Greenlee William J: Bicyclic heterocycle derivatives and methods of use thereof. Schering Corporation, Neelamkavil Santhosh Francis, Boyle Craig D, Neustadt Bernard R, Chackalamannil Samuel, Greenlee William J, Bergman Jeffrey P, January 21, 2010: WO/2010/009208 (10 worldwide citation)

The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular diseas ...


8
Haslanger Martin F, Sybertz Edmund J Jr, Neustadt Bernard R, Smith Elizabeth M: Neutral metalloendopeptidase inhibitors in the treatment of hypertension.. Schering, October 20, 1993: EP0566157-A1 (7 worldwide citation)

The method of treating hypertension with neutral metalloendopeptidase (NMEP) inhibitors, NMEP inhibitors in combination with atrial peptides, and NMEP inhibitors in combination with angiotensin converting enzyme inhibitors, as well as pharmaceutical compositions therefor, are disclosed.


9
Mallams Alan K, Dasmahapatra Bimalendu, Neustadt Bernard R, Demma Mark, Vaccaro Henry A: Quinazoline derivatives useful in cancer treatment. Schering Corporation, Mallams Alan K, Dasmahapatra Bimalendu, Neustadt Bernard R, Demma Mark, Vaccaro Henry A, BANERJEE Krishna G, January 25, 2007: WO/2007/011623 (7 worldwide citation)

The present invention provides compounds of Formula I (wherein X, m, R1, R2, R3, and R4 are as defined herein), or a pharmaceutically acceptable salt, solvate or ester thereof. The present invention also provides compositions comprising these compounds that are useful for treating cellular prolifera ...


10
NEUSTADT Bernard R, LIU Hong: Dérivés hétérocycles bicycliques et procédés dutilisation de ceux-ci, Bicyclic heterocycle derivatives and methods of use thereof. Merck Sharp & Dohme, NEUSTADT Bernard R, LIU Hong, December 22, 2011: WO/2011/159657 (7 worldwide citation)

Compounds of structural formula I: are GPR119 agonists and are useful for the treatment, control or prevention of disorders responsive to agonism of GPR119, such as metabolic-related disorders such as type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, ...